Skip to content

Could monotherapy with Kaletra become an option for HIV treatment?

Initiating HAART with any one of four 3 x 5 drug choices leads to longest survival in San Francisco

Two-year data continue to show promise for T-20

Once daily Reverset safe and effective over ten days in treatment-naïve and –experienced patients

Tenofovir has viral potency, a good lipid and safety profile, and should be available for first line HAART says study

WHO: we are still on track for 3 x 5 HIV treatment goal

FDA warns that tenofovir has not been proven to be safe for HIV/HBV coinfection

Intergrase inhibitor trial results have potential implications for treatment strategies

UK government announces £116m of extra HIV funding for UN agencies